Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USPSTF Recommends Low-Dose CT Lung Cancer Screening For People At High Risk

This article was originally published in The Gray Sheet

Executive Summary

Since the task force advised against screening for lung cancer nine years ago, new research supports annual screening for lung cancer with low-dose computed tomography in smokers ages 55 to 79 years who have significant cumulative tobacco smoke exposure.

You may also be interested in...



News Briefs: Lung Screening Recs; Stryker Purchase; CMS News

Federal task force issued final recommendations advising CT screening for people at high risk for lung cancer. Stryker acquired Patient Safety Technologies. CMS announced updates on accountable care organizations. More news briefs.

CT’s Benefits Outweigh Risks In Some 55-And-Older Smokers, Societies Find

The new recommendations are based on a meta-analysis of eight randomized trials and 13 cohort studies of low-dose computed tomography screening for lung cancer, including the large, federally funded National Lung Screening Trial.

Annual CT Screening Offers Big Mortality Benefit To Smokers – NCI

Annual screening of current and former heavy smokers with computed tomography can reduce their risk of dying from lung cancer by about 20%, according to a large National Cancer Institute-backed study.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel